Proactive Investors USA & Canada
Biogen Idec Surpasses $5 Billion in 2011 Annual Revenue
MarketWatch (press release)
RITUXAN(R) (rituximab) revenues from our unconsolidated joint business arrangement were $1.0 billion for the year, a decrease of 7% versus prior year as a result of certain royalties from individual countries expiring and a charge of approximately $50 ...
Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call Transcript